Marker Therapeutics to Present at Three Upcoming Healthcare Conferences
HOUSTON, Nov. 8, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate in three upcoming healthcare conferences. Mr. Hoang will participate in a panel discussion titled "Drug Pricing and Development Challenges" at the CEO Life Sciences and Pharmaceuticals Symposium on November 13, 2018 in New York City, and will give corporate overviews at the Piper Jaffray 30th Annual Healthcare Conference on November 27, 2018 in New York City and at the Evercore ISI HealthconX Conference on November 28, 2018 in Boston.
CEO Life Sciences and Pharmaceuticals Symposium
Title: Drug Pricing and Development Challenges
Date: Tuesday, November 13, 2018
Time: 5:00pm – 6:30pm (EST)
Location: Yellow Room, 107 East 16th Street, New York City
Piper Jaffray 30th Annual Healthcare Conference
Date: Tuesday, November 27, 2018
Time: 12:00pm – 12:25pm (EST)
Location: Lotte New York Palace, Holmes 1, 4th Floor
Evercore ISI HealthconX Conference
Date: Wednesday, November 28, 2018
Time: 10:35am – 10:55am (EST)
Location: Boston Harbor Hotel, South Atlantic Room, 2nd Floor
Webcasts for the Piper Jaffray and Evercore ISI conferences will be made available at https://markertherapeutics.com/events/
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing several innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904) 862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our multi-antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™ program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
SOURCE Marker Therapeutics, Inc.